EICHOR
● Not Yet Recruiting
A Single-arm, Multi-center, Phase II Exploratory Clinical Study to Evaluate the Efficacy and Safety of Trilaciclib in Preventing Myelosuppression Caused by Topoisomerase I Inhibitor Type ADC Drugs
Condition: Tumor Patients · Sponsor: Tianjin Medical University Cancer Institute and Hospital
About this study
Evaluation of the efficacy and safety of Trilaciclib in preventing myelosuppression caused by topoisomerase I inhibitor type ADC drugs
This description comes directly from the study's public registry record.
Talk to the study team
Zhansheng Jiang Zhansheng Jiang · 008618526812877 · 18526812877@163.com
Always discuss trial participation with your own doctor first.
Locations (2)
| Tianjin Medical University Cancer Institute & Hospital | Tianjin, China | — |
| Tianjin Medical University Cancer Institute & Hospital | Tianjin, China | — |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07736001